About Bard PowerPort Lawsuit
Bard PowerPort devices are implantable infusion ports used primarily for chemotherapy delivery and IV access in cancer patients. These devices allow easier administration of medications while allowing patients to maintain more normal lifestyles. However, certain PowerPort models have experienced malfunction, including septal leakage, port fracture, and valve dysfunction, resulting in therapy delays and serious complications.
Cancer patients relying on these ports for critical treatment depend on them functioning properly. Malfunction can delay essential chemotherapy, leading to disease progression. Additionally, port failure can cause blood clots, infections, and vascular damage. Bard failed to adequately warn about known failure modes and risks of serious complications.
If you had a Bard PowerPort implanted and experienced malfunction, infection, thrombosis, or required surgical removal due to complications, you may have a significant claim against Bard (now owned by Becton Dickinson) for design defect and failure to warn.